Nasus Pharma Ltd — Investor Relations & Filings
Filings indexed
63
across all filing types
Latest filing
2026-03-28
Director's Dealing
Country
US
United States of America
Listing
US
NSRX
Nasus Pharma Ltd. is a clinical-stage pharmaceutical company that develops powder-based intranasal (PBI) therapies for acute and life-threatening medical emergencies. The company utilizes its proprietary Nasax® technology platform, which is engineered for the rapid and precise delivery of drugs to the bloodstream. This powder formulation technology aims to provide faster onset of action, higher bioavailability, and improved stability compared to traditional injectable or liquid formulations. Its lead product candidate, NS002, is an intranasal epinephrine powder developed for the emergency treatment of severe allergic reactions (anaphylaxis).
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 3 - Nasus Pharma Ltd (0002029039) (Issuer) | 2026-03-28 | English | |
| 3 - Nasus Pharma Ltd (0002029039) (Issuer) | 2026-03-28 | English | |
| 3 - Nasus Pharma Ltd (0002029039) (Issuer) | 2026-03-28 | English | |
| 3 - Nasus Pharma Ltd (0002029039) (Issuer) | 2026-03-28 | English | |
| 3 - Nasus Pharma Ltd (0002029039) (Issuer) | 2026-03-28 | English | |
| 3 - Nasus Pharma Ltd (0002029039) (Issuer) | 2026-03-28 | English |
Browse filings by year
3 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
13 filings
| |||||
| 33067769 | 3 - Nasus Pharma Ltd (0002029039) (Issuer) | 2026-03-28 | English | ||
| 33067514 | 3 - Nasus Pharma Ltd (0002029039) (Issuer) | 2026-03-28 | English | ||
| 33067512 | 3 - Nasus Pharma Ltd (0002029039) (Issuer) | 2026-03-28 | English | ||
| 33067511 | 3 - Nasus Pharma Ltd (0002029039) (Issuer) | 2026-03-28 | English | ||
| 33067509 | 3 - Nasus Pharma Ltd (0002029039) (Issuer) | 2026-03-28 | English | ||
| 33067506 | 3 - Nasus Pharma Ltd (0002029039) (Issuer) | 2026-03-28 | English | ||
| 33067504 | 3 - Nasus Pharma Ltd (0002029039) (Issuer) | 2026-03-28 | English | ||
| 33067502 | 3 - Nasus Pharma Ltd (0002029039) (Issuer) | 2026-03-28 | English | ||
| 33066458 | POS AM - Nasus Pharma Ltd (0002029039) (Filer) | 2026-03-27 | English | ||
| 33040249 | 20-F - Nasus Pharma Ltd (0002029039) (Filer) | 2026-03-25 | English | ||
| 32325287 | 6-K Filing | 2026-02-13 | English | ||
| 32325265 | 6-K Filing | 2026-01-29 | English | ||
| 13710817 | 6-K | 2026-01-20 | English | ||
|
2025
2 filings
| |||||
| 13710824 | 6-K | 2025-12-29 | English | ||
| 13710825 | 6-K | 2025-12-22 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Nasus Pharma Ltd via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34418/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34418 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34418 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34418 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34418}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Nasus Pharma Ltd (id: 34418)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.